Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 8,615 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disorder Clear all
Active, not recruiting Not applicable Interventional

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

NCT06611553
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

NCT02138253
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Coronado, California • La Jolla, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03387137
View directory record Official record
Conditions
RSV Infection
Interventions
RSV 6120/∆NS2/1030s, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 60 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 27, 2026, 8:27 PM EDT
Not listed Phase 4 Interventional

17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts

NCT01712295
View directory record Official record
Conditions
Warts
Interventions
17% Salicylate with ethyl pyruvate, Salicylates
Drug
Lead sponsor
Grossman, Michael, D.P.M.
Individual
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 27, 2026, 8:27 PM EDT
Completed No phase listed Observational

COVID Breath Test - Ancon

NCT04760639
View directory record Official record
Conditions
Covid19
Interventions
Breath test
Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 27, 2026, 8:27 PM EDT
Not listed Phase 2 Interventional

A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis

NCT03465111
View directory record Official record
Conditions
Scleritis
Interventions
ACTH (adrenocorticotropic hormone) gel
Drug
Lead sponsor
Metropolitan Eye Research & Surgery Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Palo Alto, California • Palisades Park, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 1 Interventional

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

NCT00134134
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
efalizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

NCT04677114
View directory record Official record
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 1 Interventional

A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)

NCT00001006
View directory record Official record
Conditions
HIV Infections
Interventions
AS-101
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

NCT00737204
View directory record Official record
Conditions
HIV Infections, Fatigue
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users

NCT00164372
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Peer Education Intervention
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
15 Years to 30 Years
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

NCT03973775
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Cream 5%
Drug
Lead sponsor
Saptalis Pharmaceuticals LLC
Industry
Eligibility
2 Months to 65 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Dinuba, California • Long Beach, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

NCT00001057
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
7
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PrEP Intervention for People Who Inject Substances and Use Methamphetamine

NCT04523519
View directory record Official record
Conditions
HIV Infections
Interventions
Video directly observed therapy with contingency management, Integrated Next-Step Counseling
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years · Male only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Making PrEP Smart: An HIV Testing and PrEP Electronic Support Tool ("SmartPrEP" App) for Women on PrEP

NCT05111119
View directory record Official record
Conditions
HIV/AIDS
Interventions
Making PrEP Smart
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

NCT06896136
View directory record Official record
Conditions
Diarrhea Infectious
Interventions
VENBETA6890, Placebo
Drug
Lead sponsor
Mark Klempner
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Not applicable Interventional Results available

Cognitive Rehabilitation in Post-COVID-19 Syndrome

NCT06136871
View directory record Official record
Conditions
Post-COVID-19 Syndrome
Interventions
CO-OP Procedures, Inactive Control Group
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 27, 2026, 8:27 PM EDT
Not listed Phase 1 Interventional

Treatment of Advanced AIDS Patients With Dextrin Sulfate

NCT00004987
View directory record Official record
Conditions
HIV Infections
Interventions
Dextrin 2-sulfate
Drug
Lead sponsor
Steinhart Medical Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rural Dementia Caregiver Project

NCT04428112
View directory record Official record
Conditions
Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions
Building Better Caregivers Workshop, Attention Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 27, 2026, 8:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

NCT06005298
View directory record Official record
Conditions
Alcohol Use Disorder, Risk Behavior, Health, Dysbiosis, HIV Infections
Interventions
Screening, Brief Intervention, Referral to Treatment (SBIRT)
Behavioral
Lead sponsor
Shirish S Barve
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

NCT03512275
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 27, 2026, 8:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

NCT00389311
View directory record Official record
Conditions
HIV Infections
Interventions
Normosol-R, Nonoxynol-9, Gastrointestinal instrumentation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 27, 2026, 8:27 PM EDT